FDA Closes Potential Food Additive Option In Warnings To Supplement Firms

Six warnings to firms marketing products containing DMHA mark a change in the agency's supplement market oversight with explanation that non-dietary ingredients that have not been approved for use in food are deemed unsafe and are not allowed for use in supplements under an exemption for food additives Other three firms FDA warned were advised the ingredient phenibut found in their products also isn't eligible for use in supplements.

The nine dietary supplement firms the US Food and Drug Administration warned in letters published April 16 are in the first group warned about ingredients the agency notes in categorizations it has launched to state whether it has made a conclusive or preliminary determination that a substance is ineligible for use in supplements.

Six of the warnings also marked another first in the agency's oversight of the vitamin, mineral and supplement product market....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

Germany Leading Enforcement Against Unsafe Supplements Sold In EU

 
• By 

Germany was more active than any other EU member in the second quarter in submitting notifications to the Commission regarding problematic food supplements.

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.

EFSA: ‘A Dose Of Estragole Without A Harmful Effect Cannot Be Established’

 
• By 

Dietary supplements containing estragole may have to be removed from the European Union market due to carcinogenic risk, according to a draft scientific opinion from EFSA that is currently out for consultation.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

More from Policy & Regulation

FDA RIF Delays Response On NPA NMN Petition

 

Due to staff reductions at FDA ordered by DOGE, but accounting for return of some employees after their dismissals were rescinded, agency missed July 31 deadline it had set for responding to the NPA’s petition and expects to respond by Sept. 30.

US FDA’s Kratom Focus Pivots To ‘Concentrated Synthetic Byproduct That Is An Opioid’

 

Explaining he was a heroin addict for 14 years more than 40 years ago “because it was so available,” Secretary Kennedy says “our agencies have been asleep in the wheel” but “now we're going to wake up and we're going to start to stop this before it starts.”

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.